

Title (en)

LONG ACTING ERYTHROPOIETINS THAT MAINTAIN TISSUE PROTECTIVE ACTIVITY OF ENDOGENOUS ERYTHROPOIETIN

Title (de)

ERYTHROPOETINE MIT LANGZEITWIRKUNG ZUR AUFRECHTERHALTUNG DER GEWEBESCHUTZAKTIVITÄT VON ENDOGENEM ERYTHROPOETIN

Title (fr)

ERYTHROPOIETINES A ACTION LONGUE QUI MAINTIENNENT L'ACTIVITE PROTECTRICE DU TISSU D'UNE ERYTHROPOIETINE ENDOGENE

Publication

**EP 1545586 A4 20070926 (EN)**

Application

**EP 03755796 A 20030909**

Priority

- US 0328073 W 20030909
- US 40902002 P 20020909

Abstract (en)

[origin: WO2004022577A2] Methods for increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new chemically modified long acting erythropoietins, methods of producing the chemically modified long acting erythropoietins, and compositions comprising the chemically modified long acting erythropoietins.

IPC 1-7

**A61K 38/18**; **A61K 38/16**; **A61K 38/22**; **C07K 1/10**; **C07K 14/505**

IPC 8 full level

**A61K 38/18** (2006.01); **A61K 47/48** (2006.01); **C07K 14/505** (2006.01)

CPC (source: EP KR)

**A61K 38/16** (2013.01 - KR); **A61K 38/18** (2013.01 - KR); **A61K 38/1816** (2013.01 - EP); **A61K 47/549** (2017.07 - EP); **A61K 47/60** (2017.07 - EP); **A61P 7/00** (2017.12 - EP); **A61P 7/06** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 1/10** (2013.01 - KR); **C07K 14/505** (2013.01 - EP KR)

Citation (search report)

- [X] WO 0187329 A1 20011122 - HOFFMANN LA ROCHE [CH]
- [A] UREÑA PABLO: "Treatment of anemia in chronic renal failure by a long-activating activator of erythropoiesis", PRESSE MEDICALE, vol. 31, no. 11, 23 March 2002 (2002-03-23), ISSN: 0373-0101, pages 505 - 514, XP002444891
- See references of WO 2004022577A2

Citation (examination)

WO 0181405 A2 20011101 - AMGEN INC [US]

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated extension state (EPC)

AL LT LV MK

DOCDB simple family (publication)

**WO 2004022577 A2 20040318**; **WO 2004022577 A3 20040916**; AU 2003273297 A1 20040329; AU 2003273297 A8 20040329; BR 0314152 A 20050712; CA 2497960 A1 20040318; CN 101371920 A 20090225; CN 1729015 A 20060201; EA 007812 B1 20070227; EA 200500473 A1 20051027; EP 1545586 A2 20050629; EP 1545586 A4 20070926; IL 174178 A0 20060801; IS 7731 A 20050308; JP 2006511468 A 20060406; KR 20050083682 A 20050826; MX PA05002617 A 20050908; NO 20051714 L 20050606; PL 375741 A1 20051212; ZA 200505423 B 20080827

DOCDB simple family (application)

**US 0328073 W 20030909**; AU 2003273297 A 20030909; BR 0314152 A 20030909; CA 2497960 A 20030909; CN 03824915 A 20030909; CN 200810149087 A 20030909; EA 200500473 A 20030909; EP 03755796 A 20030909; IL 17417806 A 20060308; IS 7731 A 20050308; JP 2004534745 A 20030909; KR 20057004045 A 20050309; MX PA05002617 A 20030909; NO 20051714 A 20050406; PL 37574103 A 20030909; ZA 200505423 A 20030909